WHAT IS CLAIMED IS:

1. A compound of structural formula I:



I

or a pharmaceutically acceptable salt thereof, wherein;

V, W, X and Z are independently selected from CH and N;

R^1 is H, C_{1-3} alkyl, C_{1-3} alkoxy, F, or Cl;

R^2 is S(O)n R^6, COR6 or CHO, wherein

n is 0, 1 or 2; and

R^6 is $N(R^3)_2$ or C_{1-3} alkyl;

R^3 is independently H or C_{1-3} alkyl;

Ar is aryl or heteroaryl;

R^4 and R^5 are independently selected from:

(1) hydrogen,

(2) aryl, either unsubstituted or substituted with

(a) halo

(b) C_{1-3} alkoxy,

(c)-$N(C_{1-3}$ alkyl$)_2$,

(d) C_{2-4} alkanoyl, or

(e) aryl;

(3) nitro,

(4) C_{1-5} alkyl,

(5) C_{1-5} alkoxy,

(6) hydroxy-C_{1-3} alkyl,

(7) carboxy,
(8) halo,
(9) C_{1-5} alkylthio,
(10) C_{1-5} alkoxycarbonyl,
(11) pyridylcarbonyl,
(12) benzoyl,
(13) phenyl-C_{1-3} alkoxy,
(14) pyridyl, either unsubstituted or substituted with C_{1-3} alkyl or C_{1-3} alkoxy,
(15) C3-6 cycloalkyl,
(16) oxazolyl,
(17) thiazolyl,
(18) triazolyl,
(19) phenoxy or
(20) C_{2-6} alkanoyl.

2. The compound of Claim 1 wherein Ar is phenyl, of structural formula I(a)



I(a)

or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 2 wherein X and Z are both nitrogen and V and W are both -CH=.

4. The compound of Claim 3 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

5. The compound of Claim 4 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarbonyl, and C_{1-3} alkoxyphenyl.

6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table:

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2NH_2$	
$-SO_2NH_2$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2C_2H_5$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2NH_2$	
$-SO_2NH_2$	

R^2	
$-SO_2NH_2$	
$-SO_2NH_2$	
$-SO_2C_2H_5$	
$-SO_2CH(CH_3)_2$	
$-SO_2CH(CH_3)_2$	

7. The compound of Claim 1 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b);



I(b)

or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 7 wherein X and Z are both nitrogen and V and W are both -CH=.

9. The compound of Claim 8 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or $-SO_2N(C_{1-3}$ alkyl)$_2$.

10. The compound of Claim 9 wherein the heteroaryl group, Ar, is selected from: thiazolyl, thiadiazolyl, pyrazolyl, pyridyl, benzothiazolyl, oxazolyl, pyridothiazolyl, benzoxazolyl, quinolyl, pyrazinyl, thienyl, isoxazolyl, pyrimidinyl, benzimidazolyl, oxadiazolyl and imidazolyl.

11. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, selected from those depicted in the following Table:

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2NH_2$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	$-Ar(R^4)(R^5)$
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2N(CH_3)_2$	

R^2	
$-SO_2NH_2$	
$-SO_2CH_3$	
$-SO_2C_2H_5$	
$-SO_2C_2H_5$	

R^2	$-Ar(R^4)(R^5)$
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2C_2H_5$	
$-SO_2C_2H_5$	

12. The compound of Claim 1 wherein one of X and Z is N and the other is -CH= of structural formula I(c):



I(c)

or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 12 wherein X is N, Z is -CH= and V and W are both -CH=.

14. The compound of Claim 13, or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table

R^2	$-Ar(R^4)(R^5)$
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

R^2	$-Ar(R^4)(R^5)$
$-SO_2CH_3$	
$-SO_2CH_3$	
$-SO_2CH_3$	

15. The compound of Claim 12 wherein X is -CH=, Z is N and V and W are both -CH=.

16. The compound of Claim 15 or a pharmaceutically acceptable salt thereof, selected from those depicted in the following Table;

R^2	X	
$-SO_2CH_3$		
$-SO_2CH_3$		
$-SO_2CH_3$		

R^2	X	
$-SO_2CH_3$		
$-SO_2CH_3$		
$-SO_2CH_3$		
$-SO_2CH_3$		
$-SO_2CH_3$		
$-SO_2CH_3$		









17. The compound of Claim 1 wherein R^2 is -COR6 of structural formula I(d):



I(d)

or a pharmaceutically acceptable salt thereof.

18. The compound of Claim 17 or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table:

R^6	
$-CH_3$	
$-CH_3$	
$-CH_3$	

19. The compound of Claim 1 of structural formula I(e), wherein one of V or W is nitrogen and the other is -CH= .



1(e)

20. The compound of Claim 19 wherein R^1 and R^3 ar both hydrogen.

21. The compound of Claim 20 wherein R^2 is $-SO_2CH_3$ or $-SO_2NH_2$.

22. The compound of Claim 21 selected from the compounds depicted in the following TABLE

V	W	
—N=	–CH=	
–CH=	—N=	
–CH—	—N=	
–CH—	—N=	

23. A method of treating Y5 receptor mediated diseases which comprises administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Claim 1 that selectively antagonizes the Y5 receptor in preference to the other NPY receptors.

24. The method of Claim 23 wherein the Y5 mediated disease is obesity.

25. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a selective Y5 antagonist.